ADMA Biologics, Inc.
General ticker "ADMA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $4.1B (TTM average)
ADMA Biologics, Inc. does not follow the US Stock Market performance with the rate: -15.9%.
Estimated limits based on current volatility of 1.5%: low 7.50$, high 7.79$
Factors to consider:
- Total employees count: 685 (+9.8%) as of 2024
- US accounted for 94.8% of revenue in the fiscal year ended 2023-12-31
- Top business risk factors: Market volatility, Profitability concerns, Pandemic risks, Geopolitical risks, Regulatory and compliance
- Current price 44.8% below estimated low
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [14.06$, 23.13$]
- 2026-12-31 to 2027-12-31 estimated range: [14.84$, 24.19$]
Financial Metrics affecting the ADMA estimates:
- Positive: with PPE of 29.4 at the end of fiscal year the price was neutral
- Positive: Operating profit margin, % of 37.53 > 18.39
- Positive: Return on assets ratio (scaled to [-100,100]) of 19.05 > 6.06
- Negative: -0.16 < Industry inventory ratio change (median), % of 0
- Negative: Shareholder equity ratio, % of 76.46 > 64.29
- Positive: Investing cash flow per share per price, % of -0.48 > -0.60
- Negative: negative Industry operating income (median)
- Negative: -0.75 < Inventory ratio change, % of -0.24
- Positive: -0.02 < Operating cash flow per share per price, % of 1.11
Short-term ADMA quotes
Long-term ADMA plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $258.21MM | $426.45MM | $510.17MM |
| Operating Expenses | $236.58MM | $287.47MM | $318.73MM |
| Operating Income | $21.63MM | $138.98MM | $191.44MM |
| Non-Operating Income | $-49.87MM | $-13.27MM | $-8.79MM |
| Interest Expense | $25.03MM | $13.93MM | $7.11MM |
| R&D Expense | $3.30MM | $1.81MM | $4.76MM |
| Income(Loss) | $-28.24MM | $125.71MM | $182.66MM |
| Taxes | $0.00MM | $-71.96MM | $35.73MM |
| Net Income(Loss)* | $-28.24MM | $197.67MM | $146.93MM |
| Stockholders Equity | $135.21MM | $349.02MM | $477.32MM |
| Assets | $329.18MM | $488.68MM | $624.24MM |
| Operating Cash Flow | $8.80MM | $118.67MM | $50.40MM |
| Capital expenditure | $4.98MM | $8.57MM | $22.57MM |
| Investing Cash Flow | $-4.98MM | $-8.57MM | $-21.89MM |
| Financing Cash Flow | $-38.99MM | $-58.30MM | $-44.02MM |
| Earnings Per Share** | $-0.13 | $0.85 | $0.62 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.